Get the Stockscreener App
175.00
0.06%
-0.11
After Hours:
175.00
Icon Plc stock is traded at $175.00, with a volume of 1.60M.
It is down -0.06% in the last 24 hours and up +3.50% over the past month.
Icon is a global late-stage contract research organization that provides drug development and clinical trial services to pharmaceutical, biotechnology, and medical-device firms. While the vast majority of its revenue comes from clinical research, Icon also offers ancillary services such as laboratory and imaging capabilities. The company is headquartered in Ireland.
See More
Previous Close:
$175.11
Open:
$172.46
24h Volume:
1.60M
Relative Volume:
1.25
Market Cap:
$14.13B
Revenue:
$8.19B
Net Income/Loss:
$758.19M
P/E Ratio:
19.06
EPS:
9.18
Net Cash Flow:
$1.06B
1W Performance:
+0.07%
1M Performance:
+3.50%
6M Performance:
-4.57%
1Y Performance:
-41.61%
1-Day Range:
$170.27
$176.06
1-Week Range:
$164.00
$180.07
52-Week Range:
$125.10
$310.54
Icon Plc Stock (ICLR) Company Profile
Compare ICLR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ICLR
Icon Plc
|
175.00 | 12.87B | 8.19B | 758.19M | 1.06B | 9.18 |
|
TMO
Thermo Fisher Scientific Inc
|
479.46 | 179.95B | 43.21B | 6.58B | 6.17B | 17.29 |
|
DHR
Danaher Corp
|
190.05 | 137.90B | 24.01B | 3.41B | 4.86B | 4.70 |
|
IDXX
Idexx Laboratories Inc
|
641.14 | 51.04B | 4.04B | 985.66M | 774.34M | 12.01 |
|
A
Agilent Technologies Inc
|
123.24 | 35.19B | 6.79B | 1.22B | 1.09B | 4.26 |
|
IQV
Iqvia Holdings Inc
|
187.22 | 31.26B | 15.70B | 1.24B | 2.01B | 6.91 |
Icon Plc Stock (ICLR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Sep-09-25 | Downgrade | Jefferies | Buy → Hold |
| Sep-03-25 | Upgrade | Rothschild & Co Redburn | Neutral → Buy |
| Aug-21-25 | Downgrade | Citigroup | Buy → Neutral |
| Jul-24-25 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Apr-29-25 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-14-25 | Downgrade | TD Cowen | Buy → Hold |
| Apr-10-25 | Downgrade | Barclays | Overweight → Equal Weight |
| Mar-21-25 | Downgrade | Goldman | Buy → Neutral |
| Jan-07-25 | Initiated | RBC Capital Mkts | Outperform |
| Oct-24-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Oct-14-24 | Initiated | Redburn Atlantic | Neutral |
| Sep-18-24 | Initiated | Leerink Partners | Outperform |
| Jun-06-24 | Initiated | Goldman | Buy |
| Dec-15-23 | Initiated | Truist | Buy |
| Sep-13-23 | Initiated | TD Cowen | Outperform |
| Jan-17-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Jan-13-23 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-09-22 | Upgrade | BofA Securities | Neutral → Buy |
| Sep-07-22 | Initiated | UBS | Buy |
| Aug-25-22 | Initiated | Credit Suisse | Neutral |
| May-24-22 | Initiated | Guggenheim | Buy |
| Apr-25-22 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Apr-12-22 | Upgrade | Deutsche Bank | Hold → Buy |
| Sep-27-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Aug-05-21 | Resumed | Credit Suisse | Outperform |
| Jul-23-21 | Upgrade | Citigroup | Neutral → Buy |
| Jul-14-21 | Initiated | Citigroup | Neutral |
| Apr-13-21 | Resumed | BofA Securities | Neutral |
| Apr-01-21 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Mar-08-21 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Mar-03-21 | Initiated | Barclays | Equal Weight |
| Mar-01-21 | Upgrade | UBS | Neutral → Buy |
| Feb-26-21 | Upgrade | Truist | Hold → Buy |
| Jul-24-20 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-20-20 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-26-20 | Upgrade | Barclays | Equal Weight → Overweight |
| Mar-02-20 | Initiated | Deutsche Bank | Hold |
| Jan-27-20 | Downgrade | SunTrust | Buy → Hold |
| Jan-08-20 | Initiated | Wells Fargo | Equal Weight |
| Jan-07-20 | Initiated | Citigroup | Neutral |
| Sep-23-19 | Downgrade | KeyBanc Capital Markets | Overweight → Sector Weight |
| Jul-26-19 | Upgrade | UBS | Sell → Neutral |
| Jan-25-19 | Upgrade | Mizuho | Neutral → Buy |
| Oct-26-18 | Upgrade | Evercore ISI | In-line → Outperform |
| Oct-09-18 | Initiated | UBS | Sell |
| Apr-03-18 | Downgrade | Evercore ISI | Outperform → In-line |
| Feb-15-18 | Reiterated | Mizuho | Neutral |
| Jan-19-18 | Initiated | Evercore ISI | Outperform |
| Oct-27-17 | Reiterated | Barclays | Equal Weight |
| Sep-11-17 | Initiated | BofA/Merrill | Buy |
| Jul-31-17 | Upgrade | SunTrust | Hold → Buy |
| Jul-27-17 | Reiterated | Mizuho | Neutral |
| Jun-29-17 | Upgrade | Jefferies | Hold → Buy |
View All
Icon Plc Stock (ICLR) Latest News
TD Cowen Maintains Icon PLC(ICLR.US) With Hold Rating, Cuts Target Price to $183 - 富途牛牛
Baird Financial Group Inc. Cuts Holdings in Icon Plc $ICLR - MarketBeat
Brokerages Set Icon Plc (NASDAQ:ICLR) PT at $219.64 - MarketBeat
ICON plc (ICLR): Assessing Valuation as CEO Transition Confirms Stability and 2025 Guidance - simplywall.st
Jefferies rates IQVIA, Charles River as Buy, ICON as Hold - MSN
Jefferies Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $175 - 富途牛牛
ICON Plc and Zealand Pharma’s Petrelintide Study: A Key Update for Investors - TipRanks
ICON plc’s Latest Study on Kedrion IVIG 10% for Chronic ITP: A Market Perspective - TipRanks
Will ICON’s (ICLR) Leadership Transition Reinforce Operational Continuity or Signal a Strategic Shift? - simplywall.st
Truist Financial Reaffirms Their Buy Rating on Icon (ICLR) - The Globe and Mail
A Quick Look at Today's Ratings for Icon PLC(ICLR.US), With a Forecast Between $220 to $225 - 富途牛牛
ICON plc Reaffirms 2025 Financial Guidance Amid CEO Transition - The Globe and Mail
Icon CEO Steve Cutler to retire, Barry Balfe to succeed - TipRanks
ICON Announces CEO Transition: Dr. Steve Cutler to Retire, Barry Balfe to Take Over - AInvest
ICON plc Announces CEO Changes, Effective October 1, 2025 - MarketScreener
ICON plc Appoints Barry Balfe to the Board - MarketScreener
ICON's Leadership Transition and Market Implications: Succession Strategy and Operational Continuity in Growth-Stage Biotech Firms - AInvest
ICON names Barry Balfe as new CEO effective October 1 By Investing.com - Investing.com Australia
Icon CEO Steve Cutler to Retire; Barry Balfe to Take Reins - MarketScreener
ICON names Barry Balfe as new CEO effective October 1 - Investing.com
ICON Promotes Barry Balfe to CEO Position - AInvest
Icon Promotes COO Barry Balfe to CEO Role - MarketScreener
ICON Announces CEO Transition Effective October 1, 2025 - TipRanks
ICON Announces CEO Transition - Business Wire
ICON’s Strategic Positioning in the Evolving CRO Landscape - AInvest
Baird Maintains Icon PLC(ICLR.US) With Buy Rating, Maintains Target Price $224 - 富途牛牛
Healthcare Stocks to Watch: argenx, ICON, and Edwards Lifesciences with Long-Term Potential - AInvest
ICON plc to Participate at Upcoming Investor Conferences - PharmiWeb.com
ICON plc to Participate at Upcoming September 2025 Investor Conferences - BioSpace
ICON plc Announces Participation in September 2025 Investor Conferences - TipRanks
ICON plc Announces Participation in Upcoming Investor Conferences - AInvest
ICON’s SWOT analysis: stock outlook amid industry headwinds and opportunities - Investing.com
Icon (ICLR) Stock Price, News & Analysis - MarketBeat
ICON’s Interim Financials Prompt Fresh Questions About Operational Agility and Efficiency for ICLR Investors - Yahoo Finance
Does ICON’s (ICLR) Interim Update Reveal New Clues About Efficiency in Clinical Research Outsourcing? - simplywall.st
ICON plc Releases Interim Financial Statements for 2025 - The Globe and Mail
AstraZeneca and Icon Plc’s Study on ATTR Amyloidosis: Key Insights for Investors - TipRanks
ICON Properties Plc (Malawi) declared a final dividend of 0.15 MWK per share - AfricanFinancials
ICON plc (ICLR) Investor Outlook: Navigating a 23% Upside Potential Amidst Market Volatility - DirectorsTalk Interviews
Earnings call transcript: ICON plc beats Q2 2025 earnings expectations - Investing.com
Citi Downgrades Icon PLC(ICLR.US) to Hold Rating, Cuts Target Price to $200 - 富途牛牛
ICON plc Halts COVID Vaccine Study Due to BARDA Stop Work Notice - AInvest
Healthcare Sector Rebound: Is Now the Time to Buy High-Quality CROs Like ICON? - AInvest
ICON suspends COVID vaccine study after BARDA notice - MSN
Icon Plc (NASDAQ:ICLR) Receives Average Recommendation of “Moderate Buy” from Analysts - Defense World
Icon Suspends COVID Vaccine Study After BARDA Notice, Impacting H2 2025 Revenue - AInvest
ICON plc Halts COVID Vaccine Study Following BARDA Notice - MSN
Icon PLC Shares Jump 4.26% on $250M Volume as Analysts Target 25% Gains Despite 462nd Rank - AInvest
BARDA Stops ICON COVID Vaccine Study, Company Suspends New Enrollments - AInvest
ICON suspends COVID vaccine study after BARDA notice to sponsor - Seeking Alpha
Icon Plc Stock (ICLR) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.33%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):